Jan Albert Vos.

Schonewille, M.D., Jan Albert Vos, M.D., Ph.D., Paul J. Nederkoorn, M.D., Ph.D., Marieke J.H. Wermer, M.D., Ph.D., Marianne A.A. Van Walderveen, M.D., Ph.D., Julie Staals, M.D., Ph.D., Jeannette Hofmeijer, M.D., Ph.D., Jacques A. Van Oostayen, M.D., Ph.D., Geert J.D., Ph.D., Jelis Boiten, M.D., Ph.D., Patrick A. Brouwer, M.D., Bart J. Emmer, M.D., Ph.D., Sebastiaan F. De Bruijn, M.D., Ph.D., Lukas C. Van Dijk, M.D., L. Jaap Kappelle, M.D., Ph.D., Rob H. Lo, M.D., Ewoud J. Van Dijk, M.D., Ph.D., Joost de Vries, M.D., Ph.D., Paul L.M. De Kort, M.D., Ph.D., Willem Jan J. Van Rooij, M.D., Ph.D., Jan S.P. Van den Berg, M.D., Ph.D., Boudewijn A.A.M. Van Hasselt, M.D., Leo A.M.The manuscript was prepared by the first and last authors, with input from all the authors and the assistance of a professional article writer who was also employed by Gilead Sciences. All of the decision was made by the authors to send the manuscript to get publication. End-Point Assessments Secondary and Principal end points were assessed in cohorts 1 to 4. The primary end point was the area beneath the curve for the viral load, as established with the use of a quantitative RT-PCR assay, that was performed on nasal-clean samples attained after administration of the first treatment dose through the finish of the quarantine period .